RU2762089C2 - ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53 - Google Patents

ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53 Download PDF

Info

Publication number
RU2762089C2
RU2762089C2 RU2018131120A RU2018131120A RU2762089C2 RU 2762089 C2 RU2762089 C2 RU 2762089C2 RU 2018131120 A RU2018131120 A RU 2018131120A RU 2018131120 A RU2018131120 A RU 2018131120A RU 2762089 C2 RU2762089 C2 RU 2762089C2
Authority
RU
Russia
Prior art keywords
arg
peptide
pro
prt
artificial
Prior art date
Application number
RU2018131120A
Other languages
English (en)
Russian (ru)
Other versions
RU2018131120A (ru
RU2018131120A3 (enExample
Inventor
Варда РОТТЕР
Моше ОРЕН
Перри ТАЛ
Шей АЙЗЕНБЕРГЕР
Ави БЕН-ШИМОН
Original Assignee
Иеда Рисеч Энд Девелопмент Ко. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иеда Рисеч Энд Девелопмент Ко. Лтд. filed Critical Иеда Рисеч Энд Девелопмент Ко. Лтд.
Publication of RU2018131120A publication Critical patent/RU2018131120A/ru
Publication of RU2018131120A3 publication Critical patent/RU2018131120A3/ru
Application granted granted Critical
Publication of RU2762089C2 publication Critical patent/RU2762089C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2018131120A 2016-02-04 2017-02-03 ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53 RU2762089C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291003P 2016-02-04 2016-02-04
US62/291,003 2016-02-04
PCT/IL2017/050132 WO2017134671A1 (en) 2016-02-04 2017-02-03 Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53

Publications (3)

Publication Number Publication Date
RU2018131120A RU2018131120A (ru) 2020-03-05
RU2018131120A3 RU2018131120A3 (enExample) 2020-06-25
RU2762089C2 true RU2762089C2 (ru) 2021-12-15

Family

ID=58108701

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018131120A RU2762089C2 (ru) 2016-02-04 2017-02-03 ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53

Country Status (8)

Country Link
US (1) US11230578B2 (enExample)
EP (1) EP3411390A1 (enExample)
JP (2) JP7072508B2 (enExample)
CN (1) CN108884137B (enExample)
AU (1) AU2017214733B2 (enExample)
CA (1) CA3012302A1 (enExample)
RU (1) RU2762089C2 (enExample)
WO (1) WO2017134671A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016002721A2 (pt) 2013-08-07 2018-07-10 Yeda Research And Development Company Ltd. peptídeos capazes de reativar p53 mutantes
US20220251159A1 (en) * 2016-02-04 2022-08-11 Yeda Research And Development Co., Ltd Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
CA3012302A1 (en) 2016-02-04 2017-08-10 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
EP4121441A1 (en) * 2020-03-16 2023-01-25 Yeda Research and Development Co. Ltd Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
CN112578106B (zh) * 2020-04-13 2022-04-22 南京大学 一种纳米孔道单分子蛋白质测序仪
CN112921032A (zh) * 2020-12-29 2021-06-08 苏州中科先进技术研究院有限公司 一种引物对、探针、试剂盒及其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013036208A1 (en) * 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5294605A (en) * 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
US5614393A (en) 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5969120A (en) 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
US6184205B1 (en) 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5711376A (en) 1995-12-07 1998-01-27 Marathon Oil Company Hydraulic fracturing process
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
AU7238098A (en) 1997-05-15 1998-12-08 Kyowa Hakko Kogyo Co. Ltd. Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants
HUP0201215A2 (en) * 1998-12-02 2002-08-28 Pfizer Prod Inc Methods and compositions for restoring conformational stability of a protein of the p53 family
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
BR0207068A (pt) 2001-01-26 2004-12-21 Inhibitex Inc Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
WO2002068601A2 (en) 2001-02-28 2002-09-06 Skubitz Keith M Small peptides capable of modulating the function of cd66 (ceacam) family members
US20070128657A1 (en) 2002-01-23 2007-06-07 El-Gewely Mohamed R Molecular libraries
US7361747B2 (en) 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
RU2007138027A (ru) 2005-03-14 2009-04-20 Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем (Us) Биоактивные пептиды fus-1 и комплексы полипептидов с наночастицами
GB0514538D0 (en) * 2005-07-14 2005-08-24 Ludwig Inst Cancer Res Variant polypeptide and screening assay
WO2009112075A1 (en) 2008-03-13 2009-09-17 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
US8287845B2 (en) 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
CN101805738B (zh) * 2009-11-12 2012-03-21 昆明理工大学 早老综合征所致ALT肿瘤的特有p53突变蛋白-p53N236S及其应用
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
BR112016002721A2 (pt) * 2013-08-07 2018-07-10 Yeda Research And Development Company Ltd. peptídeos capazes de reativar p53 mutantes
CA3012302A1 (en) 2016-02-04 2017-08-10 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013036208A1 (en) * 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ARNAU J. et al. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins, Protein expression and purification, 2006, V. 48, N. 1, p.1-13. *
BUCZEK O. et al. Post-translational amino acid isomerization: a functionally important D-amino acid in an excitatory peptide, Journal of Biological Chemistry, 2005, V. 280, N. 6, p.4247-4253. *
CHEN X. et al. Fusion protein linkers: property, design and functionality, Advanced drug delivery reviews, 2013, V. 65, N. 10, p.1357-1369. *
FREED-PASTOR W. A. et al. Mutant p53: one name, many proteins, Genes and development, 2012, V. 26, N. 12, p.1268-1286. *
HEITZ F. et al. Twenty years of cell‐penetrating peptides: from molecular mechanisms to therapeutics, British journal of pharmacology, 2009, V. 157, N. 2, p.195-206. *
LIU J. et al. Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering, PloS one, 2014, V. 9, N. 1, p.e85755. *
MADHUMALAR A. et al. Dimerization of the core domain of the p53 family: a computational study, Cell Cycle, 2009, V. 8, N. 1, p.137-148. *
MADHUMALAR A. et al. Dimerization of the core domain of the p53 family: a computational study, Cell Cycle, 2009, V. 8, N. 1, p.137-148. QIU S. et al. A small peptide derived from p53 linker region can resume the apoptotic activity of p53 by sequestering iASPP with p53, Cancer letters, 2015, V. 356, N. 2, p.910-917. ЧУМАКОВ П. М. Белок р53 и его универсальные функции в многоклеточном организме, Успехи биологической химии, 2007, V. 47, N. 1, с.3-52. ВИЛЬГЕЛЬМ А. Э. и др. Координированное взаимодействие мультифункциональных членов семейства p53 влияет на важнейшие процессы в многоклеточных организмах, Молекулярная биология, 2011, V. 45, N. 1, с.180-197. ARNAU J. et al. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins, Protein expression and purification, 2006, V. 48, N. 1, p.1-13. FREED-PASTOR W. A. et al. Mutant p53: one name, many proteins, Genes and development, 2012, V. 26, N. 12, p.1268-1286. TSAO M. S. et al. Prognostic and *
MAEDA Y. et al. Engineering of functional chimeric protein G-VargulaLuciferase, Analytical biochemistry, 1997, V. 249, N. 2, p.147-152. *
PAKULA A.A. et al. Genetic analysis of protein stability and function, Annual review of genetics, 1989, V. 23, N. 1, p.289-310. *
QIU S. et al. A small peptide derived from p53 linker region can resume the apoptotic activity of p53 by sequestering iASPP with p53, Cancer letters, 2015, V. 356, N. 2, p.910-917. *
TSAO M. S. et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer, Journal of clinical oncology, 2007, V. 25, N. 33, p.5240-5247. *
ZHAO M. et al. Intracellular cargo delivery using tat peptide and derivatives, Medicinal research reviews, 2004, V. 24, N. 1, p.1-12. *
ВИЛЬГЕЛЬМ А. Э. и др. Координированное взаимодействие мультифункциональных членов семейства p53 влияет на важнейшие процессы в многоклеточных организмах, Молекулярная биология, 2011, V. 45, N. 1, с.180-197. *
ЧУМАКОВ П. М. Белок р53 и его универсальные функции в многоклеточном организме, Успехи биологической химии, 2007, V. 47, N. 1, с.3-52. *

Also Published As

Publication number Publication date
CN108884137B (zh) 2022-04-05
US11230578B2 (en) 2022-01-25
RU2018131120A (ru) 2020-03-05
CN108884137A (zh) 2018-11-23
AU2017214733B2 (en) 2022-09-29
WO2017134671A1 (en) 2017-08-10
JP2022112518A (ja) 2022-08-02
US20190048053A1 (en) 2019-02-14
EP3411390A1 (en) 2018-12-12
JP7072508B2 (ja) 2022-05-20
CA3012302A1 (en) 2017-08-10
JP2019512004A (ja) 2019-05-09
AU2017214733A1 (en) 2018-09-06
RU2018131120A3 (enExample) 2020-06-25

Similar Documents

Publication Publication Date Title
US11028127B2 (en) Peptides capable of reactivating p53 mutants
RU2762089C2 (ru) ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53
US10040836B2 (en) Peptides for the treatment of neurodegenerative diseases
AU2012232642B2 (en) Neuroprotective peptides
CA2773935C (en) Peptides for the treatment of oxidative stress related disorders
AU2019300567B2 (en) Peptide compounds and therapeutic uses of same
US10906937B2 (en) Peptides and compositions comprising same and uses thereof in the treatment of diseases
US20220251159A1 (en) Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
CA2919855A1 (en) Peptides capable of reactivating p53 mutants
CA3167139A1 (en) Peptide compounds and methods of treating diseases using same
US20230127559A1 (en) Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein